Published : 28 Jan 2014
In February 2014: Godwyn Francis, Business Development – Head, Aagami, will be attending Bio India (Feb 10-12, 2014) at Bangalore and Bio Asia 2014 (February 17-19, 2014) at Hyderabad, India. The key objective of attending these events is to showcase Aagami's global clients' licensing, co-development partnering opportunities.
Aagami regularly participates in Global events in Lifesciences, which are very productive platforms to facilitate partnerships. Most recently, Aagami CEO Mr Dinesh Jain participated in Biotech showcase as well as JP Morgan, meeting more than 50 companies. Many of these meetings proved to be very fruitful.
During Bio India and Bio Asia 2014, Aagami will have the following opportunities, as key focus areas for discussion:
Client 1: A Louisiana based Biotech Company specializing in innovative cancer treatment and currently looking for co-development/licensing opportunities with companies having focus in Oncology and/or Cardiology
Client 2: An Innate Immune Drug Development Company based in Ireland seeking Co-Development/Partnership opportunity in Oncology and STEMI with. Their lead compound is a 'first-in-class' fully humanized monoclonal antibody inhibiting toll-like receptor-2 (TLR2).
Client 3: - European Biotech Company with an award winning technology which is a Biological alternative to PEGylation. The technology extends plasma half-life (10-100 fold), improves in vivo activity, allows less frequent and lower dosing combined with better patient tolerability. It is patent-protected and prolongs circulation significantly. The technology is available for licensing.
More details on the above can be provided on request, and are also available on Bio India and Bio Asia 2014 online partnering platform.
Godwyn looks forward to meeting companies who are keen to explore partnering, collaboration models, investments, to further strengthen their pipeline.
For further details please write to us on godwyn@aagami.com or call us on: +1-630-364-1837 OR +91-787-501-6957